In doxorubicin (DOX)-resistant breast cancer cells, FOXO1 induces therapeutic resistance by activating MRP1, whereas in K562 DOX-resistant leukemia cells, FOXO3 has been confirmed to be an important regulator of MRP1 (65, 66). Here, FOXO3 is linked to breast carcinoma.